减重大战再添中国玩家:翰森奥莱泊肽III期成功,国产GLP-1/GIP双靶点加速入场

E药经理人
Mar 10

中国本土企业在GLP-1双靶点减重药领域正加速追赶全球第一梯队。如果把过去两年的全球医药产业趋势浓缩为几个关键词,“减重药革命”一定位列其中。并且,进入2026年后,这一赛道仍然是全球医药产业最炙手可热的领域之一。肥胖已成为全球最严峻的慢性疾病挑战之一。世界卫生组织数据显示,目前全球超过6.5亿成年人受到肥胖困扰,而中国成人超重与肥胖的合计患病率已超过50%。长期以来,肥胖治疗缺乏真正有效且可长期...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10